Alfresa Holdings Corporation
ARHCF
Other OTC11.87
USD
- -
- -
ISIN
JP3126340003
Return %
Stock
S&P500
1Y
- -
24.99
3Y
- -
70.19
5Y
-36.52
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ryuji Arakawa
- Full Time Employees
- 12,517
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 1-1-3 Otemachi Tokyo Japan 100-0004
- IPO Date
- Jun 8, 2020
- Website
- alfresa.com
- Similar Companies
- Business
- Alfresa Holdings Corporation, established on September 29, 2003 and headquartered at 1-1-3 Otemachi, Chiyoda-ku, Tokyo, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment; it operates dispensing pharmacies and related businesses as Japan's leading ethical pharmaceuticals wholesaler with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 2025. The company operates through six primary business segments: ethical pharmaceuticals wholesaling, which delivers pharmaceuticals, diagnostic reagents, medical devices, materials and nutritional foods from 207 nationwide distribution centers to hospitals, clinics and dispensing pharmacies; self-medication products wholesaling, providing over-the-counter drugs, health foods and supplements to drugstores and pharmacies as a total healthcare merchandising wholesaler; manufacturing, producing active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents and medical devices at eight bases compliant with GMP and QMS standards, including contract manufacturing; dispensing pharmacy and related businesses, operating 177 community-based family pharmacies supporting prevention to terminal care with home healthcare enhancements; regenerative medicine-related business, encompassing cell material supply, specified cell-processed products and CMO/CDMO services; and overseas business, featuring joint ventures like REMEJE PHARMACEUTICALS in China and Alfresa Codupha Healthcare Vietnam for medical devices and reagents primarily in Asia. Alfresa Holdings maintains a nationwide network across Japan with subsidiaries including Alfresa Corporation, Shikoku Alfresa, TS Alfresa, Tohoku Alfresa and others; it targets healthcare providers, pharmacies, drugstores and patients while advancing Total Supply Chain Services integrating development, manufacturing, distribution, sales and post-marketing surveillance. Recent developments include a March 2025 memorandum of understanding with Minaris Regenerative Medicine for collaborative cell therapy development, manufacturing and distribution utilizing Alfresa's logistics; a June 2025 strategic partnership and capital investment with HekaBio to accelerate biopharma and MedTech commercialization in CNS and regenerative medicine across Japan and Asia-Pacific; a November 2025 basic business alliance with K Pharma including investment in bonds with share warrants to establish iPS cell-derived regenerative medicine supply chains for products like KP8011; a January 2025 capital alliance with Medley via share exchange to bolster digital transformation synergies in pharmacy electronic records; and the May 2024 opening of the Tsukuba Distribution Center, alongside the launch of the 25-27 Mid-term Management Plan targeting ¥3.33 trillion net sales by fiscal 2027 under Vision 2032.